This presentation contains forward-looking statements that involve substantial risks and uncertainties. Kiromic makes such forward- looking statements pursuant to the safe harbor provisions of the United States Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as: "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements regarding: Kiromic's current and anticipated IND applications including statements regarding the scope of and timing for submission of an IND application; the Deltacel™ product platform; the sponsored research agreement and the data that will be generated as a result of such collaboration; the timing for submitting and activating Kiromic's IND applications; the benefits of utilizing non-genetically engineered Gamma Delta T cells as our first in-human study; Kiromic's ability to achieve its objectives; and the timing for the initiation and successful completion of Kiromic's clinical trials of its product candidates. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in our Annual Report on Form 10-K for the year ended December 31, 2021, and as detailed from time to time in our SEC filings. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Such forward-looking statements relate only to events as of the date of this press release. We undertake no obligation to update any forward-looking statements except to the extent required by law.
PAGE
| 2
PAGE
| 3
Contents
The Kiromic Difference
Diamond AITM (Artificial Intelligence)
Gamma Delta T-cell (GDT) Therapy:
Mechanism of Action (MOA), Product Pipeline, cGMP Manufacturing
Current Status and Path Forward
The Kiromic Difference
Kiromic BioPharma is the only cell therapy company combining AI-drivengenetically edited Gamma Delta T-cells(GDT) with proprietary targeting technology to address solid malignancies.
PAGE
| 4
Allogeneic,
Gamma
Off-the-shelf,
Diamond
T-Cell Therapy from
Delta
A.I. Neural
Healthy Donors,
T-Cell (GDT)
Network
Versus Frail Cancer
Platform
Patients
Solid
In-House
Solid
cGMP
Malignancies
Malignancies
Manufacturing
(~90% of all cancers)
(~90% of all cancers)
Strategic Competitive Landscape
6 Known Companies (including Kiromic) in the Gamma Delta T Cell Therapy space. No Known Competitors with AI-drivenTechnology Combined
with a Gamma Delta CAR-T Delivery Platform.
AI-DRIVEN
CAR-GDT
PAGE
| 5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Kiromic Biopharma Inc. published this content on 21 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 November 2022 15:19:04 UTC.
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
KIROMIC BIOPHARMA, INC. 
